STAT - Reporting from the frontiers of health and medicine

Politics

Biotech

First Opinion

By Uchenna Ikediobi

Pharmalot Did FDA unfairly treat Catalyst by approving a similar drug from another company?
Health ‘What’s my real identity?’: As DNA ancestry sites gather more data, the answer for consumers often changes
Pharmalot Lawmakers contend WHO pain treatment guidelines are really Purdue ‘marketing materials’
Health The Ebola response effort is struggling. Experts say these steps could help
Health California names former Google scientist as the state’s ‘mental health czar’

Exclusive analysis of biotech, pharma, and the life sciences

Daily, market-moving coverage of biotech and pharma

Inside intelligence on the NIH, the FDA, and Congress

Profiles of the power players shaping the industry

Analysis of the latest scientific developments

Glaxo revamps sales rep compensation as part of an effort to compete in the cancer market
Vertex and U.K. agency make competing proposals as logjam over cystic fibrosis meds continues
Debate erupts over whether Sarepta’s rare disease drug has enough clinical data to determine cost-effectiveness

Special Report

Politics

Biotech

Business

Biotech

Health

Politics A new Senate health package includes surprisingly aggressive drug pricing reforms
In the Lab MIT professor is accused of claiming others’ scientific discoveries as his own
Health ‘What’s my real identity?’: As DNA ancestry sites gather more data, the answer for consumers often changes
Health Tech Google’s AI improves accuracy of lung cancer diagnosis, study shows
Pharma Four of the world’s largest drug companies are teaming with Verily. Here is what they get